The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Polymorphism of the N -acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis
Abstract
Antituberculosis drug-induced hepatitis is one of the most prevalent drug-induced liver injuries. Isoniazid is the major drug incriminated in this hepatotoxicity. Isoniazid is mainly metabolized to hepatotoxic intermediates by N-acetyltransferase (NAT). However, the association of polymorphic NAT acetylator status and antituberculosis drug-induced hepatitis is debatable. To determine whether acetylator status is a risk factor for antituberculosis drug-induced hepatitis, we genotyped NAT2 in 224 incident tuberculosis patients who received antituberculosis treatment. Antituberculosis drug-induced hepatitis was diagnosed based on a positive isoniazid rechallenge test and exclusion of viral hepatitis. Acetylator status was determined by genotyping NAT2 in patients using a polymerase chain reaction with restriction fragment length polymorphism. Univariate analysis and logistic regression analysis were used to evaluate the risk factors of isoniazid-induced hepatitis. Thirty-three patients (14.7%) were diagnosed with antituberculosis drug-induced hepatitis. Slow acetylators had a higher risk of hepatotoxicity than rapid acetylators (26.4% vs. 11.1%, P = .013). Among patients with hepatotoxicity, slow acetylators had significantly higher serum aminotransferase levels than rapid acetylators. Logistic regression showed that slow-acetylator status (odds ratio [OR], 3.66; 95% CI, 1.58-8.49; P = .003) and age (OR, 1.09; 95% CI, 1.04-1.14; P < .001) were the only 2 independent risk factors for antituberculosis drug-induced hepatitis. In conclusion, slow-acetylator status of NAT2 is a significant susceptibility risk factor for antituberculosis drug-induced hepatitis. Additionally, slow acetylators are prone to develop more severe hepatotoxicity than rapid acetylators. Regular monitoring of serum aminotransferase levels is mandatory in patients receiving antituberculosis treatment, especially in slow acetylators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106
Isoniazid Liver Injury: Clinical Spectrum, Pathology, and Probable Pathogenesis
MITCHELL, J. R., ZIMMERMAN, H. J., ISHAK, K. G., THORGEIRSSON, U. P., TIMBRELL, J. A., SNODGRASS, W. R., & NELSON, S. D. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-2-181 · Cited by 505
BLUM, M., GRANT, D. M., McBRIDE, W., HEIM, M., & MEYER, U. A. (1990) · DNA and Cell Biology · doi:10.1089/dna.1990.9.193 · Cited by 435
Isoniazid-Associated Hepatitis in 114 Patients
Black, M., Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., & Epler, G. R. (1975) · Gastroenterology · doi:10.1016/s0016-5085(19)32568-5 · Cited by 370
Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
De, K., Snider, D. E., & Caras, G. J. (1978) · PubMed · doi:10.1164/arrd.1978.117.6.991 · Cited by 368
Lee, W. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331706 · Cited by 305
Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid.
Ryan, D. E., Ramanathan, L., Iida, S., Thomas, P. E., Haniu, M., Shively, J. E., Lieber, C. S., & Levin, W. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)88984-0 · Cited by 304
Mitchell, J. R., Thorgeirsson, U. P., Black, M., Timbrell, J. A., Snodgrass, W. R., Potter, W. Z., Jollow, D. J., & Keiser, H. R. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518170 · Cited by 300
Cited by
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Bernal, W., Auzinger, G., Dhawan, A., & Wendon, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60274-7 · Cited by 996
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Navarro, V. J., & Senior, J. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052270 · Cited by 811
Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review
Tostmann, A., Boeree, M. J., Aarnoutse, R. E., De Lange, W. C. M., Van Der Ven, A. J. A. M., & Dekhuijzen, R. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05207.x · Cited by 781
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management
Ramappa, V., & Aithal, G. P. (2013) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2012.12.001 · Cited by 508
Abboud, G., & Kaplowitz, N. (2007) · Drug Safety · doi:10.2165/00002018-200730040-00001 · Cited by 479
Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug–Induced Hepatitis
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Chang, S.-C., Chiang, C.-H., Chang, F.-Y., & Lee, S.-D. (2003) · Hepatology · doi:10.1053/jhep.2003.50144 · Cited by 426
Self-citationCurrent Concepts of Mechanisms in Drug-Induced Hepatotoxicity
Russmann, S., Kullak-Ublick, G., & Grattagliano, I. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803097 · Cited by 412
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Leise, M. D., Poterucha, J. J., & Talwalkar, J. A. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.09.016 · Cited by 356
Risk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347
Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives
Fontana, R. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.032 · Cited by 313
Idiosyncratic Drug Reactions: Current Understanding
Uetrecht, J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105150 · Cited by 304
Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis
Unissa, A. N., Subbian, S., Hanna, L. E., & Selvakumar, N. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.09.004 · Cited by 300
Mechanisms of Immune-Mediated Liver Injury
Adams, D. H., Ju, C., Ramaiah, S. K., Uetrecht, J., & Jaeschke, H. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq009 · Cited by 298
Pharmacogenomics: Challenges and Opportunities
Roden, D. M., Altman, R. B., Benowitz, N. L., Flockhart, D. A., Giacomini, K. M., Johnson, J. A., Krauss, R. M., McLeod, H. L., Ratain, M. J., Relling, M. V., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00007 · Cited by 282
Pharmacogenetics-based tuberculosis therapy research group, Azuma, J., Ohno, M., Kubota, R., Yokota, S., Nagai, T., Tsuyuguchi, K., Okuda, Y., Takashima, T., Kamimura, S., et al. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1429-9 · Cited by 278
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 274
Review article: drug hepatotoxicity
CHANG, C. Y., & SCHIANO, T. D. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03307.x · Cited by 264
Isoniazid metabolism and hepatotoxicity
Wang, P., Pradhan, K., Zhong, X.-B., & Ma, X. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.07.014 · Cited by 257
Idiosyncratic Drug Reactions: Past, Present, and Future
Uetrecht, J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700186p · Cited by 257
Antituberculosis drugs and hepatotoxicity
YEW, W. W., & LEUNG, C. C. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00941.x · Cited by 256
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
McDonagh, E. M., Boukouvala, S., Aklillu, E., Hein, D. W., Altman, R. B., & Klein, T. E. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000062 · Cited by 146
Devarbhavi, H., Singh, R., Patil, M., Sheth, K., Adarsh, C. K., & Balaraju, G. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07279.x · Cited by 86
Nicoletti, P., Devarbhavi, H., Goel, A., Venkatesan, R., Eapen, C. E., Grove, J. I., Zafer, S., Bjornsson, E., Lucena, M. I., Andrade, R. J., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2100 · Cited by 61
Wang, D., Para, M. F., Koletar, S. L., & Sadee, W. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283498ee9 · Cited by 53
Metadata
- Authors
- Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Lai, S.-L., Yang, S.-Y., Chang, F.-Y., & Lee, S.-D.
- Venue
- Hepatology
- Published
- 2002-04
- Volume
- 35
- Issue
- 4
- Pages
- 883-889
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2095134596
- Cited by
- 432
- References
- 32
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.